Sirolimus-based calcineurin inhibitor withdrawal immunosuppressive regimen in kidney transplantation: A single center experience

Clinical and Experimental Nephrology

Volumn 14, Issue 3, 2010, Pages 248-255

  Alarrayed, Sameer M ^a   El Agroudy, Amgad E ^a   Alarrayed, Ahmad S ^a   Al Ghareeb, Sumaya M ^a   Garadah, Taysir S ^a   El Sharqawi, Salah Y ^a   Al Aradi, Ali H ^a   Dandi, Balaji G ^a   Abdulla, Sadiq ^a  

^a ARABIAN GULF UNIVERSITY   (Bahrain)

Author keywords

Conversion; Immunosuppression; Sirolimus

Indexed keywords

ANTIBIOTIC AGENT; AZATHIOPRINE; BASILIXIMAB; CREATININE; CYCLOSPORIN A; GLUCOSE; METHYLPREDNISOLONE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PREDNISOLONE; PREDNISONE; RAPAMYCIN; TACROLIMUS; VALACICLOVIR; VALGANCICLOVIR; CALCINEURIN; CYCLOSPORIN; IMMUNOSUPPRESSIVE AGENT;

ACUTE GRAFT REJECTION; ADOLESCENT; ADULT; AGED; ANEMIA; ARTICLE; BACTERIAL INFECTION; CARDIOVASCULAR DISEASE; CHRONIC ALLOGRAFT NEPHROPATHY; CONTROLLED STUDY; CREATININE BLOOD LEVEL; CYTOMEGALOVIRUS INFECTION; DEATH; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG RESPONSE; DRUG SAFETY; DRUG SUBSTITUTION; DRUG WITHDRAWAL; FEMALE; GLUCOSE BLOOD LEVEL; GRAFT FAILURE; GRAFT RECIPIENT; HEPATITIS; HERPES ZOSTER; HUMAN; HYPERGLYCEMIA; IMMUNOSUPPRESSIVE TREATMENT; KIDNEY FAILURE; KIDNEY FUNCTION; KIDNEY GRAFT REJECTION; KIDNEY TRANSPLANTATION; LEUKOPENIA; LOADING DRUG DOSE; LOBAR PNEUMONIA; MAJOR CLINICAL STUDY; MALE; MOUTH ULCER; MYCOSIS; OBSERVATIONAL STUDY; PROTEINURIA; RETROSPECTIVE STUDY; RISK FACTOR; THROMBOCYTOPENIA; URINARY TRACT INFECTION; VIRUS INFECTION; BLOOD; DRUG ANTAGONISM; GRAFT REJECTION; MIDDLE AGED; PATHOPHYSIOLOGY; WITHDRAWAL SYNDROME;

ADOLESCENT; ADULT; AGED; CALCINEURIN; CREATININE; CYCLOSPORINE; FEMALE; GRAFT REJECTION; HUMANS; IMMUNOSUPPRESSIVE AGENTS; KIDNEY TRANSPLANTATION; MALE; MIDDLE AGED; RETROSPECTIVE STUDIES; SIROLIMUS; SUBSTANCE WITHDRAWAL SYNDROME;

EID: 77956645435     PISSN: 13421751     EISSN: 14377799     Source Type: Journal    
DOI: 10.1007/s10157-010-0269-0     Document Type: Article

References (40)

1. Meier-Kriesche HU, Li S, Gruessner RW, et al. Immunosuppression: evolution in practice and trends, 1994-2004. Am J Transplant. 2006;6(5):1111-1131
2. Shihab FS. Cyclosporine nephropathy: pathophysiology and clinical impact. Semin Nephrol. 1996;16:536-547
3. Halloran PF. Immunosuppressive drugs for kidney transplantation. N Engl J Med. 2004;351:2715-2729
4. Woolfson RG, Neild GH. Cyclosporine nephrotoxicity following cardiac transplantation. Nephrol Dial Transplant. 1997;12:2054-2056
5. Morales JM, Andres A, Rengel M, Rodicio JL. Influence of cyclosporine, tacrolimus and rapamycin on renal function and arterial hypertension after renal transplantation. Nephrol Dial Transplant. 2001;16:121-129
6. Morales JM. Immunosuppressive treatment and progression of histologic lesions in kidney allografts. Kidney Int. 2005;99:S124-30.
7. Nankivell BJ, Borrows RJ, Fung CL, O'Connell PJ, Chapman JR, Allen RD. Calcineurin inhibitor nephrotoxicity: longitudinal assessment by protocol histology. Transplantation. 2004;78:557-565
8. Kasiske BL, Chakkera HA, Louis TA, Ma JZ. A meta-analysis of immunosuppression withdrawal trials in renal transplantation. J Am Soc Nephrol. 2000;11:1910-1917
9. MacPhee IA, Bradley JA, Briggs JD, et al. Long-term outcome of a prospective randomized trial of conversion from cyclosporine to azathioprine treatment one year after renal transplantation. Transplantation. 1998;66:1186-1192
10. Ducloux D, Fournier V, Bresson-Vautrin C, et al. Mycophenolate mofetil in renal transplant recipients with cyclosporine-associated nephrotoxicity: a preliminary report. Transplantation. 1998;65:1504-1506
11. Weir MR, Blahut S, Drachenburg C, et al. Late calcineurin inhibitor withdrawal as a strategy to prevent graft loss in patients with suboptimal kidney transplant function. Am J Nephrol. 2004;24:379-386
12. Afzali B, Shah S, Chowdhury P, O'Sullivan H, Taylor J, Goldsmith D. Low-dose mycophenolate mofetil is an effective and safe treatment to permit phased reduction in calcineurin inhibitors in chronic allograft nephropathy. Transplantation. 2005;79:304-309
13. Kreis H, Cisterne JM, Land W. Sirolimus in association with mycophenolate mofetil induction for the prevention of acute graft rejection in renal allograft recipients. Transplantation. 2000;69:1252-1260
14. Hamdy AF, El-Agroudy AE, Bakr MA, et al. Comparison of sirolimus with low-dose tacrolimus versus sirolimus-based calcineurin inhibitor-free regimen in live donor renal transplantation. Am J Transplant. 2005;5:2531-2538
15. Vincenti F, Ramos E, Brattstrom C. Multicenter trial exploring calcineurin inhibitor avoidance in renal transplantation Transplantation. 2001 71 1282-1289.
16. Johnson RWG, Kreis H, Oberbauer R, Brattstrom C, Claesson K, Eris J. Sirolimus allows early cyclosporine withdrawal in renal transplantation resulting in improved renal function and lower blood pressure. Transplantation. 2001;72:777-786
17. Srinivas TR, Schold JD, Guerra G, et al. Mycophenolate mofetil/ sirolimus compared to other common immunosuppressive regimens in kidney transplantation. Am J Transplant. 2007;7:586-594
18. Mulay AV, Cockfield S, Stryker R, Fergusson D, Knoll GA. Conversion from calcineurin inhibitors to sirolimus for chronic renal allograft dysfunction: a systematic review of the evidence. Transplantation. 2006;82:1153-1162
19. Lai WJ, Chiang YJ, Chen Y, Chu SH. Is sirolimus a safe alternative to reduce or eliminate calcineurin inhibitors in chronic allograft nephropathy in kidney transplantation? Transplant Proc. 2004;36:2056-2057
20. Ram Peddi V, Jensik S, Pescovitz M, et al. An open-label, pilot study evaluating the safety and efficacy of converting from calcineurin inhibitors to sirolimus in established renal allograft recipients with moderate renal insufficiency. Clin Transplant. 2005;19:130-136
21. Abramowicz D, Hadaya K, Hazzan M, et al. Conversion to sirolimus for chronic renal allograft dysfunction: risk factors for graft loss and severe side effects. Nephrol Dial Transplant. 2008;23:3727-3729
22. Diekmann F, Budde K, Oppenheimer F, Fritsche L, Neumayer HH, Campistol JM. Predictors of success in conversion from calcineurin inhibitor to sirolimus in chronic allograft dysfunction. Am J Transplant. 2004;4:1869-1875 (Pubitemid 39434449)
23. Stallone G, Infante B, Schena A, et al. Rapamycin for treatment of chronic allograft nephropathy in renal transplant patients. J Am Soc Nephrol. 2005;16:3755-3763
24. Watson CJ, Firth J, Williams PF, et al. A randomized controlled trial of late conversion from CNI-based to sirolimus-based immunosuppression following renal transplantation. Am J Transplant. 2005;5:2496-2502
25. Sayegh MH, Carpenter CB. Transplantation 50 years later: progress, challenges, and promises N Engl J Med. 2004 351 2761-2766
26. Meier-Kriesche HU, Schold DJ, Srinvas TR, Kaplan B. Lack of improvement in renal allograft survival despite marked decrease in acute rejection rates over the most recent era. Am J Transplant. 2004;4:378-383
27. Pascual M, Theruvath T, Kwai T, Tolkoff-Rubin N, Cosimi AB. Strategies to improve long-term outcomes after renal transplantation. N Engl J Med. 2002;346:580-590 (Pubitemid 34438820)
28. Nankivell BJ, Borrows RJ, Fung CL, O'Connell PJ, Allen RD, Chapman JR. The natural history of chronic allograft nephropathy. N Engl J Med. 2003;349:2326-2333
29. Kopp JB, Klotman PE. Cellular and molecular mechanisms of cyclosporine nephrotoxicity. J Am Soc Nephrol. 1990;1:162-179
30. Fellstorm B, Jardine AG, Soveri I, the ALERT study Group, et al. Renal dysfunction is a strong and independent risk factor of mortality and cardiovascular complications in renal transplantation. Am J Transplant. 2005;5:1986-1991
31. Asberg A, Midtvedit K, Line PD, et al. Calcineurin inhibitor avoidance with declizumab, mycophenolate mofetil, and prednisolone in DR-matched de novo kidney transplant recipients. Transplantation. 2006;82:62-68
32. Abramowicz D, Manas D, Lao M, Cyclosporine Withdrawal Study Group, et al. Cyclosporine withdrawal from a mycophenolate mofetil-containing immunosuppressive regimen in stable kidney transplant recipients: a randomized, controlled study. Transplantation. 2002;74:1725-1734
33. Abramowicz D, Del Carmen Rial M, Vitko S, Cyclosporine Withdrawal Study Group, et al. Cyclosporine withdrawal from a mycophenolate mofetil-containing immunosuppressive regimen: results of a five-year, prospective, randomized study. J Am Soc Nephrol. 2005;16:2234-2240
34. Oberbauer R, Segoloni G, Campistol JM, Rapamune Maintenance Regimen Study Group, et al. Early cyclosporine withdrawal from a sirolimus-based regimen results in better renal allograft survival and renal function at 48 months after transplantation. Transpl Int. 2005;18:22-28
35. Mota A, Taskinen EI, Paavonen T, Rapamune Maintenance Trial, et al. Sirolimus-based therapy after early cyclosporine withdrawal results in significantly better renal histology and function at 3 years fallowing kidney transplantation. Am J Transplant. 2004;4(6):953-961
36. Pearson T, Wali R, Shidban H, Patel A, Chan L. Spare-the- Nephron (STN): one-year interim efficacy and safety of mycophenolate mofetil/sirolimus maintenance therapy after calcineurin inhibitor withdrawal in renal transplants. Am J Transplant. 2006;6(Suppl 2):432-439
37. Lebranchu Y, Thierry A, Toupannce O, et al. Efficacy on renal function of early conversion from cyclosporine to sirolimus 3 months after renal transplantation: Concept Study. Am J Transplant. 2009;9(5):1115-1123
38. Kreis H, Obernauer R, Campistol JM, For the Rapamune Maintenance Regimen Trial, et al. Long-term benefits with sirolimusbased therapy after early cyclosporine withdrawal. J Am Soc Nephrol. 2004;15:809-817
39. Powell HR, Kara T, Jones CL. Early experience with conversion to sirolimus in a pediatric renal transplant population Pediatr Nephrol. 2007 22 1773-1777
40. Saber LT, Ikeda MY, Almeida JM. Posttransplantation conversion to sirolimus-based immunosuppression: a single center experience. Transplant Proc. 2007;39:3098-3100